Research Funding

  • February 10, 2015 - April 30, 2018 - NAPTA: Optimizing clinical trial design & delivery of particle therapy for cancer , Principal Investigator . Sponsor: NIH, Sponsor Award ID: P20CA183640
  • July 1, 2002 - June 30, 2010 - SFSU/UCSF Comprehensive Cancer Partnership Program , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U56CA096216

Education

Morehouse College, Atlanta, GA, BS, 1975, Physics
Stanford University School of Medicine, Stanford,CA, MD, 1979, Medicine
University of California San Francisco, Fellow, 1981-83, Med Oncology
Stanford University School of Medicine, Stanford,CA, Resident, 1984-87, Radiation Oncology

Honors & Awards

  • 1980-1981
    Outstanding Intern of the Year (Charles R. Drew Award)
  • 1981-1982
    Fellow of the American Cancer Society
  • 1994
    UCSF Health Net Wellness Award
  • 1994-1997
    American Cancer Society Career Development Award
  • 1996-97; 1997-98; 2001-02
    "The Best Doctors in America"
  • 2002
    Fellow, American College of Radiology
  • 2002-05
    President, John Hale Medical Society
  • 2005
    10 Most Influential African Americans in the Bay Area (Healthcare)

Selected Publications

  1. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, NRG Prostate Cancer AI Consortium, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2022 Jun 08; 5(1):71.  View on PubMed
  2. Roach M. Moving Beyond Race-Based Medicine. Ann Intern Med. 2022 03; 175(3):W20.  View on PubMed
  3. Vickers AJ, Elfiky A, Freeman VL, Roach M. Race, Biology, Disparities, and Prostate Cancer. Eur Urol. 2022 05; 81(5):463-465.  View on PubMed
  4. Roach M, Hiatt RA, Black S. Commentary: Race, COVID-19 and Nursing Homes. J Infect Dis. 2022 02 15; 225(4):555-556.  View on PubMed
  5. Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson WC, Morgan TM, Mehra R, Salami SS, Vince R, Schaeffer EM, Mahal BA, Dess RT, Steinberg ML, Elashoff D, Sandler HM, Spratt DE, Kishan AU. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. JAMA Netw Open. 2021 12 01; 4(12):e2139769.  View on PubMed
  6. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, Gillessen S, APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2022 01; 160:24-60.  View on PubMed
  7. Crook J, Rodgers JP, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Murtha AD, Vigneault E, Helou J, Michalski JM, Roach M, Beyer D, Jani AB, Horwitz EM, Raben A, Pugh S, Sandler H. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526). Int J Radiat Oncol Biol Phys. 2022 04 01; 112(5):1115-1122.  View on PubMed
  8. Henríquez I, Roach M, Morgan TM, Bossi A, Gómez JA, Abuchaibe O, Couñago F. Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines. 2021 Sep 17; 9(9).  View on PubMed
  9. Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):294-303.  View on PubMed
  10. Wu SY, Wong AC, Shinohara K, Roach M, Cunha JAM, Valdes G, Hsu IC. Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation. Pract Radiat Oncol. 2021 Nov-Dec; 11(6):515-526.  View on PubMed
  11. Rogowski P, Roach M, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R, Buchner A, Stief C, Belka C, Li M. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021 Mar 09; 16(1):50.  View on PubMed
  12. Mohamad O, Roach M. Radiation Delay Is Okay, but Where Is the Evidence? JAMA Oncol. 2021 03 01; 7(3):463-464.  View on PubMed
  13. Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncol. 2021 01; 22(1):11-13.  View on PubMed
  14. Chen WC, Li Y, Lazar A, Altun A, Descovich M, Nano T, Ziemer B, Sudhyadhom A, Cunha A, Thomas H, Gottschalk A, Hsu IC, Roach M. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis. Int J Radiat Oncol Biol Phys. 2021 06 01; 110(2):429-437.  View on PubMed
  15. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CAF. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. J Clin Oncol. 2021 01 10; 39(2):136-144.  View on PubMed
  16. Hsu IC, Rodgers JP, Shinohara K, Purdy J, Michalski J, Roach M, Vigneault E, Ivker RA, Pryzant RM, Kuettel M, Taussky D, Gustafson GS, Raben A, Sandler HM. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys. 2021 07 01; 110(3):700-707.  View on PubMed
  17. Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G, Schaeffer E, Roach M, Evans CP, Hussain M. Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. JAMA Oncol. 2020 Nov 01; 6(11):1793-1800.  View on PubMed
  18. Mohamad O, Roach M. Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):337.  View on PubMed
  19. Gartrell BA, Roach M, Retter A, Sokol GH, Del Priore G, Scher HI. Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer. Invest New Drugs. 2021 04; 39(2):499-508.  View on PubMed
  20. Roach M. Editorial Comment. J Urol. 2020 11; 204(5):954.  View on PubMed

Go to UCSF Profiles, powered by CTSI